Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

NCT06426797 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Cadonilimab plus anlotinib

Sponsor

Peking University People's Hospital

Collaborators

[object Object]